Goldman M J, Wilson J M
Institute for Human Gene Therapy, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA.
J Virol. 1995 Oct;69(10):5951-8. doi: 10.1128/JVI.69.10.5951-5958.1995.
Recombinant adenoviruses are being evaluated for gene therapy of cystic fibrosis lung disease with the goal of reconstituting the expression of the cystic fibrosis transmembrane conductance regulator in pulmonary epithelia by direct administration of the virus into the airway. The therapeutic potential of recombinant adenoviruses is limited in part by the relative inefficiency by which gene transfer occurs. This study uses a human bronchial xenograft model to study adenovirus infection in the human airway in an attempt to define the molecular events that limit gene transfer. Our studies of the human airway confirm previous observations of cell lines that have indicated a two-step process for adenovirus entry, which begins with the binding of the virus to the cell through the fiber protein and continues with internalization via interactions among cellular integrins and an RGD motif (Arg-Gly-Asp) in the penton base. Furthermore, the level of maturity of the epithelia in xenografts has a major impact on gene transfer. Undifferentiated epithelia express high levels of alpha v beta 5 integrins and are easily infected with recombinant adenoviruses; gene transfer is completely inhibited with excess fiber and partially inhibited with RGD peptide and alpha v beta 5 integrin antibody. Pseudostratified epithelia do not express alpha v beta 5 integrin in differentiated columnar cells and are relatively resistant to adenovirus-mediated gene transfer; what little gene transfer occurs is inhibited by fiber but not by RGD peptide or alpha v beta 5 integrin antibody. These studies suggest that the expression of integrins in human airway epithelia limits the efficiency of gene transfer with recombinant adenoviruses. However, low-level gene transfer can occur in fully mature epithelia through alpha v beta 5 integrin-independent pathways.
重组腺病毒正被评估用于囊性纤维化肺病的基因治疗,其目标是通过将病毒直接导入气道来恢复肺上皮细胞中囊性纤维化跨膜传导调节因子的表达。重组腺病毒的治疗潜力部分受到基因转移相对低效的限制。本研究使用人支气管异种移植模型来研究腺病毒在人气道中的感染情况,试图确定限制基因转移的分子事件。我们对人气道的研究证实了之前在细胞系中的观察结果,即腺病毒进入细胞的过程分为两步,首先是病毒通过纤维蛋白与细胞结合,然后通过细胞整合素与五聚体基底中的RGD基序(精氨酸-甘氨酸-天冬氨酸)之间的相互作用实现内化。此外,异种移植中上皮细胞的成熟程度对基因转移有重大影响。未分化的上皮细胞表达高水平的αvβ5整合素,很容易被重组腺病毒感染;过量的纤维可完全抑制基因转移,RGD肽和αvβ5整合素抗体可部分抑制基因转移。假复层上皮在分化的柱状细胞中不表达αvβ5整合素,对腺病毒介导的基因转移相对抗性较强;发生的少量基因转移可被纤维抑制,但不受RGD肽或αvβ5整合素抗体抑制。这些研究表明,人气道上皮细胞中整合素的表达限制了重组腺病毒基因转移的效率。然而,通过不依赖αvβ5整合素的途径,在完全成熟的上皮细胞中也可发生低水平的基因转移。